
Gene Therapy for Kids’ Deadly Muscle Disease Fails to Reach Trial Goal
Roche Holding AG shares dropped after a trial of its gene therapy for Duchenne muscular dystrophy did not
2023-10-31 16:58

Catalent Is Linked to Regeneron’s Eye-Drug Rejection in Latest Misstep
Problems at a Catalent Inc. production facility led US regulators to deny a key drug application from Regeneron
2023-06-29 00:29

Catalent Cuts Annual Forecast More Than Expected, Delays Earnings Report Again
Catalent Inc. shares rose after the troubled contract drug manufacturer gave investors some reassurance about a slashed fiscal
2023-05-19 22:20

Drug Contractor Catalent Plunges After Annual Guidance Cut, Results Delayed
Catalent Inc. shares traded at their lowest in three years following cuts to its annual financial outlook that
2023-05-09 02:28